Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
The prognosis of MYC positive diffuse large B-cell lymphoma (DLBCL) is very poor even treated with R-CHOP regimen. Recently, dose-adjusted EPOCH-R was shown to be effective in patients with DLBCL and relapsed/refractory Burkitt lymphoma. The aim of this study is to evaluate the efficacy and toxicity of dose-adjusted EPOCH-R in patients with MYC positive diffuse large B-cell lymphoma.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Previously untreated MYC positive diffuse large B-cell lymphoma
Age range 18-70 years old
Eastern Cooperative Oncology Group performance status 0-2
Life expectancy of more than 3 months
Adequate organ function
You may not be if
Primary or secondary central nervous system involvement
Previous serious cardiac disease
History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
Pregnant or lactating women
Serious uncontrolled diseases and intercurrent infection
